Compare SUPV & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SUPV | AURA |
|---|---|---|
| Founded | 1887 | 2007 |
| Country | Argentina | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 703.9M | 631.6M |
| IPO Year | 2015 | 2021 |
| Metric | SUPV | AURA |
|---|---|---|
| Price | $7.21 | $6.33 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | $11.80 | ★ $16.60 |
| AVG Volume (30 Days) | 539.5K | ★ 933.0K |
| Earning Date | 11-16-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $32.97 | N/A |
| Revenue Next Year | $20.17 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.83 | $4.73 |
| 52 Week High | $13.55 | $9.54 |
| Indicator | SUPV | AURA |
|---|---|---|
| Relative Strength Index (RSI) | 41.62 | 41.73 |
| Support Level | $6.72 | $6.03 |
| Resistance Level | $7.59 | $7.83 |
| Average True Range (ATR) | 0.28 | 0.26 |
| MACD | 0.03 | 0.07 |
| Stochastic Oscillator | 57.45 | 41.33 |
Grupo Supervielle SA a diversified financial services group in Argentina. It offers a broad range of financial products and services including lending, savings and investments, insurance, payments and cash management services, car loans, and asset management, positioning itself as a one-stop destination for financial needs. It operates exclusively in Argentina, through the Bank, which serves as its main banking subsidiary, delivering a comprehensive suite of financial services to retail, SMEs and corporate customers. Its segments include Personal & Business Banking; Corporate Banking; Bank Treasury; Insurance; and Asset Management and Other Services (which includes IOL invertironline). The majority of the revenue is derived from Personal & Business Banking segment.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.